NCT03945253View on ClinicalTrials.gov

Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 5, 2019

Primary Completion Date

June 12, 2020

Study Completion Date

June 12, 2020

Conditions
Advanced Solid Tumors
Interventions
DRUG

ASP8374

Intravenous

Trial Locations (1)

Unknown

Site JP81001, Chuo-ku

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY